The financials
Haemonetics Corporation by the numbers
Haemonetics Corporation (HAE) reported revenue of $346M in Q4 2026 (quarter ended Mar 28, 2026), up 4.8% from the same quarter a year earlier. That came with a gross margin of 57% and net loss of $20M. For the full year FY2026, revenue was $1.33B (−2.0% year on year) and net income $97M. Its largest segment in Jun 2026 was Apheresis at $191M, 56% of the disclosed total, ahead of Med Surg at 44%.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $346M | $331M | +4.8% |
| Gross profit | $198M | $193M | +2.7% |
| Operating income | −$23M | $71M | to a loss |
| Net income | −$20M | $58M | to a loss |
| Diluted EPS | −$0.41 | $1.17 | to a loss |
| Operating | Revenue | Share |
|---|---|---|
| Apheresis | $191M | 56% |
| Med Surg | $148M | 44% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $339.4M (-40%)
Med Surg grew +6.0% year on yearApheresis +5.3% year on year
Segment Latestyear on year
- Apheresis$191.3M$191.3Myear on year +5.3%+5.3%
- Med Surg$148.1M$148.1Myear on year +6.0%+6.0%